Avana: Advanced PDE5 Inhibition for Confident Erection Management

Avana

Avana is used to treat erectile dysfunction (impotence).

Product dosage: 100mg
Package (num)	Per pill	Price	Buy
36	$4.17	$150.00 (0%)	🛒 Add to cart
60	$4.07	$250.00 $244.00 (2%)	🛒 Add to cart
88	$3.99 Best per pill	$366.67 $351.00 (4%)	🛒 Add to cart

Product dosage: 200mg
Package (num)	Per pill	Price	Buy
36	$4.92	$177.00 (0%)	🛒 Add to cart
60	$4.82	$295.00 $289.00 (2%)	🛒 Add to cart
88	$4.76 Best per pill	$432.67 $419.00 (3%)	🛒 Add to cart

Product dosage: 50mg
Package (num)	Per pill	Price	Buy
36	$3.11	$112.00 (0%)	🛒 Add to cart
60	$3.03	$186.67 $182.00 (2%)	🛒 Add to cart
88	$2.99 Best per pill	$273.78 $263.00 (4%)	🛒 Add to cart

Similar products

Avana (avanafil) is a prescription medication specifically formulated for the treatment of erectile dysfunction (ED). As a highly selective phosphodiesterase type 5 (PDE5) inhibitor, it represents a modern therapeutic option within its class, distinguished by its rapid onset of action and favorable pharmacokinetic profile. This agent works by enhancing blood flow to the penile tissue upon sexual stimulation, facilitating the achievement and maintenance of an erection suitable for satisfactory sexual activity. It is intended for use in adult males and requires a comprehensive medical evaluation prior to initiation to ensure appropriateness and safety for the individual patient.

Features

Active Pharmaceutical Ingredient: Avanafil
Standard Available Strengths: 50 mg, 100 mg, 200 mg film-coated tablets
Mechanism of Action: Selective inhibition of phosphodiesterase type 5 (PDE5)
Pharmacokinetic Profile: Rapid absorption with a median time to maximum plasma concentration (Tmax) of approximately 30-45 minutes post-dose
Elimination Half-Life: Approximately 5 hours
Primary Excretion Route: Hepatic metabolism via CYP3A4 and fecal elimination
Administration: Oral, with or without food (high-fat meals may delay absorption)

Benefits

Rapid Onset of Action: Designed to work quickly, often within 15-30 minutes, allowing for greater spontaneity.
High Selectivity for PDE5: Demonstrates a strong affinity for its target enzyme, which is associated with a potentially lower incidence of off-target side effects compared to some other agents in its class.
Efficacy Supported by Clinical Data: Proven in randomized controlled trials to significantly improve the ability to achieve and maintain an erection sufficient for successful intercourse.
Flexible Dosing Options: Availability of multiple strengths allows for individualized dosing based on efficacy and tolerability, under physician guidance.
Duration of Effect: Provides a window of opportunity for sexual activity for up to 6 hours post-administration, though response is dependent on sexual stimulation.
Improved Confidence and Sexual Satisfaction: Successful treatment of ED can lead to enhanced self-esteem, reduced anxiety related to sexual performance, and improved overall relationship satisfaction.

Common use

Avana is indicated for the management of erectile dysfunction, a condition characterized by the consistent or recurrent inability to attain and/or maintain a penile erection sufficient for satisfactory sexual performance. It is used on an as-needed basis prior to anticipated sexual activity. It is crucial to understand that avanafil does not trigger an automatic erection; sexual arousal and stimulation are necessary for the medication to be effective. Its use is common among men with various underlying causes of ED, including vasculogenic, neurogenic, and psychogenic origins, often as part of a broader treatment approach that may include lifestyle modifications and psychological counseling.

Dosage and direction

The recommended starting dose for most patients is 100 mg taken orally approximately 15-30 minutes before sexual activity. The dosage may be adjusted based on individual efficacy and tolerability to a maximum recommended dose of 200 mg or down to 50 mg. The dosing frequency should not exceed once per 24-hour period.

Administration: Swallow the tablet whole with a glass of water. It may be taken with or without food; however, consumption with a high-fat meal may delay the onset of effect.
Timing: The medication requires sexual stimulation to work. Plan to take it within the window of 15 minutes to 30 minutes prior to anticipated sexual activity.
Dose Adjustment: For patients taking concomitant potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) or who have significant hepatic impairment, a starting dose of 50 mg is recommended, and the maximum dose should not exceed 100 mg within a 24-hour period. A dose reduction should be considered in patients aged 65 years and older due to potential increased sensitivity.

Precautions

Cardiovascular Status: Sexual activity poses a potential cardiac risk. Avana is not for use in men for whom sexual activity is inadvisable due to underlying cardiovascular status. A thorough cardiovascular assessment is recommended prior to initiating any treatment for ED.
Priapism: Prolonged and sometimes painful erections lasting more than 4 hours have been reported infrequently with PDE5 inhibitors. This condition requires immediate medical attention to prevent long-term damage to penile tissues.
Effects on Vision: Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision or permanent vision loss, has been reported post-marketing in temporal association with the use of all PDE5 inhibitors. It is not possible to determine if these events are related to the drug or other factors. Patients who experience sudden vision loss in one or both eyes should stop taking Avana and seek immediate medical care.
Sudden Hearing Loss: Cases of sudden decrease or loss of hearing, sometimes accompanied by tinnitus and dizziness, have been reported. Patients experiencing these symptoms should discontinue Avana and seek prompt medical attention.
Alpha-blockers and Antihypertensives: PDE5 inhibitors, including avanafil, can potentiate the blood-pressure-lowering effects of alpha-blockers and other antihypertensive medications, which may lead to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting).

Contraindications

Avana is strictly contraindicated in the following patient populations:

Patients using any form of organic nitrates (e.g., nitroglycerin, isosorbide mononitrate or dinitrate) or nitric oxide donors (e.g., amyl nitrite “poppers”) either regularly or intermittently. The concomitant use can cause a severe and potentially life-threatening drop in blood pressure.
Patients with a known hypersensitivity to avanafil or any of the excipients in the tablet formulation.
Patients with severe hepatic impairment (Child-Pugh Class C), as the pharmacokinetics have not been studied in this population.
Patients with severe hypotension (low blood pressure), uncontrolled hypertension, or recent history of stroke, myocardial infarction, or life-threatening arrhythmia.

Possible side effect

Like all medications, Avana can cause side effects, although not everybody gets them. Most are mild to moderate and transient in nature.

Very Common (≥1/10): Headache.
Common (≥1/100 to <1/10): Flushing (feeling of warmth and redness of the face), nasal congestion, nasopharyngitis, back pain, dyspepsia (indigestion).
Uncommon (≥1/1,000 to <1/100): Dizziness, palpitations, visual disturbances (e.g., blurred vision, changes in color perception), nausea, muscle aches, insomnia, erectile prolongation.
Rare (≥1/10,000 to <1/1,000): Hypersensitivity reactions, syncope (fainting), sudden hearing loss, NAION (vision loss), priapism. This is not an exhaustive list. Patients should report any unexpected or bothersome side effects to their healthcare provider.

Drug interaction

Avana can interact with several other medications, altering its effects or increasing the risk of side effects.

Nitrates: Absolute contraindication. Concomitant use can cause profound hypotension, shock, or death.
Alpha-blockers (e.g., doxazosin, tamsulosin): Concomitant use can increase the risk of symptomatic hypotension. Dose separation or avoidance is recommended.
Potent CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin): These drugs significantly increase the plasma concentration of avanafil. The dose of Avana should not exceed 50 mg within a 24-hour period when co-administered.
Other PDE5 Inhibitors: Concomitant use with other medications for erectile dysfunction or pulmonary arterial hypertension (e.g., sildenafil, tadalafil, vardenafil) is not recommended.
Antihypertensives: Additive blood-pressure-lowering effects may occur.
Alcohol: Excessive consumption of alcohol can increase the potential for blood pressure lowering and dizziness.

Missed dose

Avana is not intended for daily scheduled use; it is taken on an as-needed basis. Therefore, the concept of a “missed dose” does not apply. Simply take the next dose when needed, prior to sexual activity, ensuring that at least 24 hours have passed since the last dose. Do not take a double dose to make up for a missed opportunity.

Overdose

In the event of a suspected overdose, which may be associated with severe manifestations of the drug’s known adverse effects (e.g., severe headache, profound hypotension, prolonged priapism, severe dizziness), immediate medical attention should be sought. Contact a poison control center or emergency room. Treatment is expected to be supportive and may include measures to stabilize blood pressure. Dialysis is not expected to be effective due to the high protein binding of avanafil.

Storage

Store below 30°C (86°F).
Keep the tablets in their original blister pack or container to protect from light and moisture.
Keep out of reach of children and pets.
Do not use the medicine after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided is based on the typical properties of the drug and may not encompass all possible scenarios, side effects, or interactions.

Reviews

“As a urologist, I find avanafil’s rapid onset to be a significant advantage for many of my patients seeking spontaneity. Its selectivity profile also tends to result in favorable tolerability in clinical practice.” – Dr. E. Lawson, MD
“After trying another medication, I switched to Avana on my doctor’s recommendation. The speed of effect is noticeably faster, which has greatly reduced performance anxiety for me.” – Patient, 54
“Clinical trial data consistently supports the efficacy of avanafil for improving erectile function scores. It’s a valuable tool in our armamentarium for managing ED, particularly for patients who have not achieved desired results with other agents.” – Clinical Researcher
“The lower incidence of visual side effects compared to some older PDE5 inhibitors was the deciding factor for my prescription. It has worked effectively with minimal discomfort.” – Patient, 61